Ajanta Pharma Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ajanta Pharma Ltd (AJPH)
The Ajanta Pharma Ltd share price today is 3,703.10, view NSE AJPH stock exchange data. Track the latest Ajanta Pharma Ltd share price with real-time updates on AJPH stock performance including market cap, day range, 52-week range and dividend yield. Access AJPH charts, earnings dates and analyst estimates to support your investment decisions.
3,703.10
-15.10(-0.41%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3,694.00
3,796.00
52 wk Range
2,329.90
3,796.00
Trading near 52-week High
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3,694.003,796.00
52 wk Range
2,329.903,796.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.61%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.61%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
AJPH Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
3,761.00
Upside
+1.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
Ajanta Pharma Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
Ajanta Pharma Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Ajanta Pharma Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Ajanta Pharma Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Analyst Ratings
11 Buy
2 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 3,761.00
(+1.56% Upside)
Ajanta Pharma Ltd Earnings Call Summary for Q1/2027
- Ajanta Pharma Q1 FY2027 revenue rose 25% YoY to INR 1,626 crores; PAT jumped 31% to INR 334 crores with 80% gross margin and 28% EBITDA margin.
- India business grew 24%, Africa 30%, U.S. 57%; Asia fell 16% due to Middle East geopolitical supply chain disruptions expected to normalize in Q2.
- Management maintained full-year high-teens revenue growth guidance; expects gross margin ~78% and EBITDA margin ~27% for FY2027, both ±100 bps.
- Company plans 5-7 U.S. generic filings in FY2027 with most launches in December quarter; INR 400 crores capex includes INR 300 crores for Pithampur expansion.
- Shares rose 1.34% to $3,442, near 52-week high of $3,598.8; declared INR 32 interim dividend per share, continuing 20-year dividend payment streak.
Last Updated: 30-07-2026, 05:24 pm
Read Full TranscriptEarnings
Latest Release
30-07-2026
EPS / Forecast
26.72 / 23.93
Revenue / Forecast
16.26B / 15.1B
Compare AJPH to Peers and Sector
Metrics to compare | AJPH | Peers Peers - average of corresponding metrics from companies closely matching AJPH: MANKIND, CIPLA, EMCURE, TORNTPHARM, LUPIN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAJPHPeersSector |
|---|---|---|---|---|
P/E Ratio | 40.9x | 30.1x | −0.3x | |
PEG Ratio | 1.86 | 0.78 | 0.00 | |
Price/Book | 10.3x | 5.5x | 2.6x | |
Price / LTM Sales | 8.0x | 6.6x | 3.1x | |
Upside (Analyst Target) | 2.6% | 7.7% | 49.0% | |
Fair Value Upside | Unlock | 5.3% | 6.3% | Unlock |
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Ajanta Pharma Ltd (AJPH) Share Price Today?
The Ajanta Pharma Ltd share price today is 3,703.10.
What is the current Ajanta Pharma Ltd (AJPH) share price and day range?
As of 18-08-2026, the Ajanta Pharma Ltd share price is 3,703.10, with a previous close of 3,718.20. The share price has ranged from 3,694.00 to 3,796.00 today, while the 52-week range spans from 2,329.90 to 3,796.00.
What Is the Ajanta Pharma Ltd Market Cap?
As of today, Ajanta Pharma Ltd market cap is 462.21B.
Does Ajanta Pharma Ltd Pay Dividends? What's The Current Dividend Yield?
The Ajanta Pharma Ltd dividend yield is 1.61%.
What Is the Ajanta Pharma Ltd (AJPH) Share Price Target?
The average 12-month share price target for Ajanta Pharma Ltd is 3,761.00, with a high estimate of 4131 and a low estimate of 3109. 11 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +1.56% Upside potential.
What Is Ajanta Pharma Ltd's Earnings Per Share (TTM)?
The Ajanta Pharma Ltd EPS (TTM) is 90.81.
When Is the Next Ajanta Pharma Ltd Earnings Date?
Ajanta Pharma Ltd will release its next earnings report on 04-11-2026.
From a Technical Analysis Perspective, Is AJPH a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Ajanta Pharma Ltd Trade On?
Ajanta Pharma Ltd is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Ajanta Pharma Ltd?
The stock symbol for Ajanta Pharma Ltd is "AJPH."
How Many Times Has Ajanta Pharma Ltd Stock Split?
Ajanta Pharma Ltd has split 4 times.
How Many Employees Does Ajanta Pharma Ltd Have?
Ajanta Pharma Ltd has 9628 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.